Jonathan Adams is CEO of NanoAntibiotics, Inc. (OTCQB:NNAB) [nanoantibiotics.com], which will soon change its name to BioVie. He has been working in pharma/biotech since graduating with his MBA from Dartmouth/Tuck in 1989, and earlier in his career assisted with the launch of Celebrex and many other drug therapies. A key member of his team is… Read more »
Since Abakan has successfully negotiated the rights to acquire a controlling interest in MesoCoat, Inc., a developer of revolutionary nanotechnology materials for cladding steel surfaces, Abakan Corp (ABKI.OB) stock is being watched carefully by investors worldwide. ABKI is trading for just a little over $1.00 currently, but investors, supporters and partners are sure that it… Read more »
Notifications